In addition, the relationship of risk score and several well-known biomarkers of glioma (IDH mutant, 1p19q co-deleted, and methylation of MGMT promoter) was analyzed to verify the clinical applicability of the signature. This evidence concerns the gene IDH1 and central nervous system cancer.